Page 258 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

214 MEDICAMENTS INDUISANTDES MODIFICATIONS COVALENTES DE L'ADN

HIROSE Y. et al., Abrogation of the Chk1-mediated G, checkpoint pathway potentiates
temozolomide-induced toxicity in a p53-independent manner in human glioblastoma
cells, Cancer Res., 2001, 61, 5843-5849.
WICK W. et al., Prevention of irradiation-induced glioma cell invasion by temozolomide
involve caspase-3 activity and cleavage of focal adhesion kinase, Cancer Res., 2002,
62, 1915-1919.
USAGES
NEWLANDS E.S. et al., Phase I trial of temolozomide( CCRG 81045 : M&B 39831 : NSC
362856), Br. J. Cancer, 1992, 65, 287-291.
PATEL M. et al., Plasma and cerebrospinal fluid pharmacokinetics of temozolomide, 31st
ann. meeting of the Amer. Soc. Clin. Oncology, 1995, 14, 1485.
ECKHARDT J.R. et a/., Phase I and pharmacokinetic trial of SCH 52365 (temozolomide)
given orally daily x 5 days. 31st ann. meeting of the Amer. Soc. Clin Oncology, 1995,
14, 1579.
REIDENBERG P. et al., Phase I clinicat and pharrnacokinetic study of temozolomide in
advanced cancer patients stratified by extentd of prior therapy, Ann. Oncology, 1996,
7 (supp. 1), 344.
DHODAPKAR M. et al., Phase I trial of temozolomide (NSC 362856) in patients with
advanced cancer, Clin. Cancer Res., 1997, 3, 1093-1100.
ECKHARDT S.G. et al., A phase I study of temozolomide combined with cisplatin (CDDP)
in patients with advanced cancer, 33rd ann. meeting of the Amer. Soc. Clin Oncology,
1997, 830.
BRITTEN C.D. et al., A phase I safety and pharmacokinetic study of temozolomide on
combination with cisplatin, Ann. Oncology, 1998, 9 (supp. 2), 442.
BROCK C.S. et al., Phase I trial of temozolomide using extended continuous oral sche-
dule, Cancer Research, 1998, 58, 4363-4367.
HAM MONO L. et al., Phase I and pharrnacokinetic trial of sequences of BCNU and temo-
zolomide (TMZ) in patients with solid neoplasms, Ann. Oncology, 1998, 9 (supp. 2),
441.
MARZOLINI C. et al., Pharrnacokinetics of temozolomide in association with fotemustine
in malignant melanoma and malignant glioma patients : comparison of oral, intravei-
nous and hepatic intra-arterial administration, Cancer Chemother. Pharmacol., 1998,
42, 433-440.
MOORE M.J. et al., A phase Il study of temozolomide in advanced unterated pancreatic
cancer lnvest. New Drugs, 1998, 16, 77-79.
THURSTON D.E., Nucleic acid targeting : therapeutic strategies for the 21 st century, Br
J. Cancer, 1999, 50 (supp. 1), 65-85.
YUNG W.K. et al., Multricenter phase Il trial of temozolomide in patients with anaplasic
astrocytoma or anaplastie oligoastrocytoma at first relapse, J. Clin. Oncol., 1999, 17,
2762-2771.
VAN BRUSSEL J. P. et al., A phase Il study of temozolomide in hormone-refractory pros-
tate cancer, Cancer Chemother. Pharmacol., 2000, 45, 509-512.
YUNG W. K. et al., A phase Il study of temozolomide versus dacarbazine in patients with
glioblastoma multiforme at first relapse, Br. J. Cancer, 2000, 83, 588-593.